David's mailing address filed with the SEC is 14610 PAWNEE LANE, , LEAWOOD, KS, 66224.
Over the last 18 years, insiders at Anavex Life Sciences have traded over $5,238,591 worth of Anavex Life Sciences stock and bought 135,460 units worth $453,776 . The most active insiders traders include Athanasios Skarpelos, Christopher U Missling und Elliot Favus. On average, Anavex Life Sciences executives and independent directors trade stock every 99 days with the average trade being worth of $335,876. The most recent stock trade was executed by Peter D.O. Donhauser on 14 June 2024, trading 2,835 units of AVXL stock currently worth $10,319.
anavex life sciences corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. anavex is currently in a phase 2a trial for alzheimer's disease (ad) with lead therapeutic, anavex 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the sigma-1 receptor. part a topline data of our ongoing phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. anavex 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: rett syndrome, as well is in epilepsy and multiple sclerosis (ms). in 2015, the company was awarded a research by the michael j. fox foundation (mjff) to study anavex 2-73 for the treatment of parkinson’s disease. headquartered in new york, anavex is an american publicly traded corporation quoted as avxl.
Anavex Life Sciences executives and other stock owners filed with the SEC include: